Telomir Pharmaceuticals (NASDAQ:TELO – Get Free Report) and Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.
Volatility & Risk
Telomir Pharmaceuticals has a beta of -0.49, suggesting that its share price is 149% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.13, suggesting that its share price is 113% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Telomir Pharmaceuticals and Lyell Immunopharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Telomir Pharmaceuticals | 1 | 0 | 1 | 1 | 2.67 |
| Lyell Immunopharma | 1 | 0 | 1 | 0 | 2.00 |
Institutional and Insider Ownership
66.1% of Lyell Immunopharma shares are held by institutional investors. 22.3% of Lyell Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Telomir Pharmaceuticals and Lyell Immunopharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Telomir Pharmaceuticals | N/A | N/A | -$16.53 million | ($0.37) | -3.59 |
| Lyell Immunopharma | $60,000.00 | 8,460.60 | -$342.99 million | ($23.02) | -1.04 |
Telomir Pharmaceuticals has higher earnings, but lower revenue than Lyell Immunopharma. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Telomir Pharmaceuticals and Lyell Immunopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Telomir Pharmaceuticals | N/A | -566.61% | -447.89% |
| Lyell Immunopharma | -794,292.69% | -96.68% | -76.00% |
Summary
Lyell Immunopharma beats Telomir Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
About Lyell Immunopharma
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Receive News & Ratings for Telomir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telomir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
